HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HUTCHMED (China) Limited

In a report released yesterday, from CLSA maintained a Buy rating on China Mobile, with a price target of HK$86.00. Currently, the analyst consensu...

China Mobile (0941) Receives a Buy from CLSA

In a report released on August 5, from CICC maintained a Buy rating on HUTCHMED (China) , with a price target of HK$23.80. The company’s shares clo...

HUTCHMED (China)  (HCM) Gets a Buy from CICC

In a report released on July 31, from UOB Kay Hian maintained a Buy rating on HUTCHMED (China) , with a price target of HK$26.00. The company’s sha...

UOB Kay Hian Remains a Buy on HUTCHMED (China)  (HCM)

In a report released on July 31, from Guotai Haitong maintained a Buy rating on HUTCHMED (China) , with a price target of HK$35.58. The company’s s...

Guotai Haitong Keeps Their Buy Rating on HUTCHMED (China)  (HCM)

Huatai Securities analyst maintained a Buy rating on HUTCHMED (China) yesterday and set a price target of HK$32.82. The company’s shares closed yes...

Huatai Securities Sticks to Their Buy Rating for HUTCHMED (China)  (HCM)

HUTCHMED (China) ( ($HK:0013) ) has provided an announcement. HUTCHMED reported strong interim results for the first half of 2026, driven by a rebo...

HUTCHMED’s China Rebound and Global FRUZAQLA Push Power 2026 Interim Results

Hutchmed (China) Limited ($HCM) announced an update on their ongoing clinical study. Hutchmed (China) Limited (HCM) is running a late‑stage study c...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HCM	$12.20	0.00%	77.12K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HCM	$12.20	0%	77.12K
3
4
5
6

HCM

Get HUTCHMED (China) Limited Data in Excel

Get HUTCHMED (China) Limited Data in Excel